Article

Hepatitis A in French hemophiliacs.

Centres Régionaux de Traitement de l'Hémophilie de Lille, France.
Vox Sanguinis (Impact Factor: 3.3). 02/1994; 67 Suppl 1:9-12; discussion 13. DOI: 10.1111/j.1423-0410.1994.tb00966.x
Source: PubMed

ABSTRACT The prevalence of serum antibodies to hepatitis A virus (HAV) in 793 hemophilia A (HA) and 89 hemophilia B (HB) patients coming from 10 French Hemophilia Centers and treated since 1986-1987 with solvent/detergent (SD)-treated products is reported. The results indicated seropositivity to HAV of 29.9% in HA and 40.4% in HB patients. There was no difference among the patients according to severity of the disease, HIV serology or administration of factor VIII during the last 12 months. Seropositivity increased with age from 5.2% in HA children to 42.4% in adults (in HB the respective prevalences in the same groups were 7.7% and 56.1%). When compared to normal controls (n = 585), the prevalence of HAV seropositivity was not excessive in HA patients (n = 206). 19/20 children exclusively treated with a very-high-purity SD-factor VIII concentrate (Centre régional de transfusion sanguine, Lille) remained HAV seronegative. Six cases of HAV contamination were reported in patients with severe HA, probably reflecting the level of HAV endemy in the normal population in France. No special risk of HAV transmission linked to the SD products used in France since 1986 had thus been identified.

0 Bookmarks
 · 
75 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: We report an outbreak of hepatitis A in nine South African hemophiliacs treated exclusively with infusions of factor VIII concentrate. The solvent/detergent (S/D) method (which does not inactivate nonenveloped viruses) was used for virus eradication. In three of six patients studied at a molecular level hepatitis A virus (HAV) complementary DNA (cDNA) amplified from serum by reverse transcription-polymerase chain reaction (RT-PCR) was identical to HAV cDNA in 1 of 14 lots (no. 53) of factor VIII tested. The plasma for lot 53 was obtained from donors in the United States: 1 of 12 samples of this source material contained the same HAV cDNA sequences. In another two patients receiving lot 53, the degree of identity between HAV cDNA in serum and that in factor VIII was only 88% and 89%, respectively, and in the sixth patient, who did not receive lot 53, it was 90%. The degree of HAV cDNA homology among five patients in an independent point-source outbreak of hepatitis A was 100%, and that in nine patients who acquired this infection sporadically in Johannesburg, Egypt, or Russia, was 93% to 100%. Whether the three hemophiliacs with low HAV cDNA homology with lot 53 acquired the infection from other unidentified virus strains contaminating factor VIII or from extraneous sources is unknown. This study provides further evidence that factor VIII concentrate prepared by the S/D method may be contaminated by the HAV, in this instance at source, and may cause hepatitis in recipients. Proof of a cause-and-effect relationship will, however, depend on animal inoculation studies.
    Hepatology 12/1995; 22(5):1363-7. · 11.19 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Although hepatitis A virus (HAV) transmission by single donor blood products is a rare event, recent reports have raised concerns about the potential for HAV transmission by pooled plasma products. In this study the removal and inactivation of HAV during production of a factor VIII concentrate, which included solvent-detergent treatment and anion-exchange chromatography steps, was assessed at 5 distinct stages of production using infectivity and, in some cases, isotopic assays. The results of these 'spiking' studies revealed an overall HAV clearance of > 8 log with appreciable contributions from antibody neutralisation, cryoprecipitation, lyophilization and possibly chromatography, but not filtration. In addition it was shown that neither solvent detergent treatment or ion-exchange chromatography reversed or impeded the neutralisation of HAV by antibody.
    Vox Sanguinis 06/1994; 67 Suppl 1:72-6; discussion 77. · 3.30 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Infectious agents, especially viruses, can be transmitted by human blood products to recipients. Of major importance are viruses such as human immunodeficiency virus 1 and 2 (HIV-1/2), hepatitis B (HBV) and hepatitis C virus (HBC), and human T-cell leukaemia virus type I and II. Also, other viruses such as cytomegalovirus, Epstein-Barr virus, human parvovirus B19, and hepatitis A and G virus can be transmitted by infected blood products. Various methods are applied to prevent the transmission of blood-borne agents to recipients, for example donor selection, testing for various infectious agents of all blood donations and viral inactivation of plasma derivatives. With all these precautionary measures, the estimated risk for infection by screened blood products in Europe and the USA is approximately 1 in 50 000 to 1 in 600 000 (for HBV, HCV and HIV-1/2) per transfused blood product. In the future, the safety of blood products will probably be increased by testing all blood donations with nucleic acid amplification techniques and by (photo)chemical decontamination of cellular blood components.
    Baillière s Clinical Anaesthesiology 06/1997;